Detalhe da pesquisa
1.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Immunity;
46(4): 577-586, 2017 04 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28410988
2.
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Mol Cell;
65(4): 730-742.e5, 2017 Feb 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28212753
3.
Fcγ-receptor tag team boosts anti-tumor immunity.
Trends Immunol;
36(7): 388-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26091729
4.
Resolution of acute inflammation bridges the gap between innate and adaptive immunity.
Blood;
124(11): 1748-64, 2014 Sep 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25006125
5.
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Nat Med;
27(10): 1797-1805, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34642489
6.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Nat Cancer;
1(12): 1153-1166, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33644766
7.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell;
33(4): 649-663.e4, 2018 04 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29576375
8.
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Oncoimmunology;
5(7): e1186323, 2016 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27622041